These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
166 related articles for article (PubMed ID: 14693782)
1. Randomised controlled trial comparing the effect of brimonidine and timolol on visual field loss after acute primary angle closure. Aung T; Oen FT; Wong HT; Chan YH; Khoo BK; Liu YP; Ho CL; See J; Thean LH; Viswanathan AC; Seah SK; Chew PT Br J Ophthalmol; 2004 Jan; 88(1):88-94. PubMed ID: 14693782 [TBL] [Abstract][Full Text] [Related]
2. Effects of Brimonidine and Timolol on the Progression of Visual Field Defects in Open-angle Glaucoma: A Single-center Randomized Trial. Yokoyama Y; Kawasaki R; Takahashi H; Maekawa S; Tsuda S; Omodaka K; Nakazawa T J Glaucoma; 2019 Jul; 28(7):575-583. PubMed ID: 31188229 [TBL] [Abstract][Full Text] [Related]
3. A randomized trial of brimonidine versus timolol in preserving visual function: results from the Low-Pressure Glaucoma Treatment Study. Krupin T; Liebmann JM; Greenfield DS; Ritch R; Gardiner S; Am J Ophthalmol; 2011 Apr; 151(4):671-81. PubMed ID: 21257146 [TBL] [Abstract][Full Text] [Related]
4. Twelve-month results of an ongoing randomized trial comparing brimonidine tartrate 0.2% and timolol 0.5% given twice daily in patients with glaucoma or ocular hypertension. Brimonidine Study Group 2. LeBlanc RP Ophthalmology; 1998 Oct; 105(10):1960-7. PubMed ID: 9787370 [TBL] [Abstract][Full Text] [Related]
5. Ongoing clinical assessment of the safety profile and efficacy of brimonidine compared with timolol: year-three results. Brimonidine Study Group II. Melamed S; David R Clin Ther; 2000 Jan; 22(1):103-11. PubMed ID: 10688394 [TBL] [Abstract][Full Text] [Related]
6. A randomized, investigator-masked, 4-week study comparing timolol maleate 0.5%, brinzolamide 1%, and brimonidine tartrate 0.2% as adjunctive therapies to travoprost 0.004% in adults with primary open-angle glaucoma or ocular hypertension. Reis R; Queiroz CF; Santos LC; Avila MP; Magacho L Clin Ther; 2006 Apr; 28(4):552-9. PubMed ID: 16750466 [TBL] [Abstract][Full Text] [Related]
7. Effects of systemic beta-blocker therapy on the efficacy and safety of topical brimonidine and timolol. Brimonidine Study Groups 1 and 2. Schuman JS Ophthalmology; 2000 Jun; 107(6):1171-7. PubMed ID: 10857839 [TBL] [Abstract][Full Text] [Related]
8. Neuroprotection for treatment of glaucoma in adults. Sena DF; Lindsley K Cochrane Database Syst Rev; 2013 Feb; 2(2):CD006539. PubMed ID: 23450569 [TBL] [Abstract][Full Text] [Related]
9. A 1-year study of brimonidine twice daily in glaucoma and ocular hypertension. A controlled, randomized, multicenter clinical trial. Chronic Brimonidine Study Group. Schuman JS; Horwitz B; Choplin NT; David R; Albracht D; Chen K Arch Ophthalmol; 1997 Jul; 115(7):847-52. PubMed ID: 9230823 [TBL] [Abstract][Full Text] [Related]
10. Treatment of patients with primary open-angle glaucoma with a fixed combination of brimonidine 0.2%/timolol 0.5%: multicenter, open-label, observational study in Germany. Thelen U; Buchholz P; Kimmich F Curr Med Res Opin; 2009 Apr; 25(4):1003-9. PubMed ID: 19275517 [TBL] [Abstract][Full Text] [Related]
11. The Low-pressure Glaucoma Treatment Study (LoGTS) study design and baseline characteristics of enrolled patients. Krupin T; Liebmann JM; Greenfield DS; Rosenberg LF; Ritch R; Yang JW; Ophthalmology; 2005 Mar; 112(3):376-85. PubMed ID: 15745762 [TBL] [Abstract][Full Text] [Related]
12. Brimonidine tartrate 0.2% twice daily vs timolol 0.5% twice daily: 1-year results in glaucoma patients. Brimonidine Study Group. Katz LJ Am J Ophthalmol; 1999 Jan; 127(1):20-6. PubMed ID: 9932994 [TBL] [Abstract][Full Text] [Related]
13. The efficacy and safety of brimonidine 0.2% compared with timolol 0.5% in glaucoma: a randomized clinical trial on Taiwanese patients. Chen MJ; Chou JC; Hsu WM; Liu JH J Chin Med Assoc; 2003 May; 66(5):276-81. PubMed ID: 12908569 [TBL] [Abstract][Full Text] [Related]
14. Changes in intraocular pressure and ocular perfusion pressure after latanoprost 0.005% or brimonidine tartrate 0.2% in normal-tension glaucoma patients. Liu CJ; Ko YC; Cheng CY; Chiu AW; Chou JC; Hsu WM; Liu JH Ophthalmology; 2002 Dec; 109(12):2241-7. PubMed ID: 12466165 [TBL] [Abstract][Full Text] [Related]
15. Clinical success and quality of life with brimonidine 0.2% or timolol 0.5% used twice daily in glaucoma or ocular t hypertension: a randomized clinical trial. Brimonidine Outcomes Study Group I. Javitt JC; Schiffman RM J Glaucoma; 2000 Jun; 9(3):224-34. PubMed ID: 10877373 [TBL] [Abstract][Full Text] [Related]
16. Dorzolamide/timolol combination versus concomitant administration of brimonidine and timolol: six-month comparison of efficacy and tolerability. Sall KN; Greff LJ; Johnson-Pratt LR; DeLucca PT; Polis AB; Kolodny AH; Fletcher CA; Cassel DA; Boyle DR; Skobieranda F Ophthalmology; 2003 Mar; 110(3):615-24. PubMed ID: 12623832 [TBL] [Abstract][Full Text] [Related]
17. Risk factors for visual field progression in the low-pressure glaucoma treatment study. De Moraes CG; Liebmann JM; Greenfield DS; Gardiner SK; Ritch R; Krupin T; Am J Ophthalmol; 2012 Oct; 154(4):702-11. PubMed ID: 22835512 [TBL] [Abstract][Full Text] [Related]
18. The short-term effect of adding brimonidine 0.2% to timolol treatment in patients with open-angle glaucoma. Yüksel N; Altintaş O; Karabaş L; Alp B; Cağlar Y Ophthalmologica; 1999; 213(4):228-33. PubMed ID: 10420106 [TBL] [Abstract][Full Text] [Related]
19. Brimonidine 0.2% given two or three times daily versus timolol maleate 0.5% in primary open-angle glaucoma. Konstas AG; Stewart WC; Topouzis F; Tersis I; Holmes KT; Stangos NT Am J Ophthalmol; 2001 Jun; 131(6):729-33. PubMed ID: 11384568 [TBL] [Abstract][Full Text] [Related]
20. A short term study of the additive effect of timolol and brimonidine on intraocular pressure. Arici MK; Sayici M; Toker M; Erdoğan H; Topalkara A Eye (Lond); 2002 Jan; 16(1):39-43. PubMed ID: 11913886 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]